News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
13,627 Results
Type
Article (173)
Company Profile (1)
Press Release (13453)
Section
Business (7077)
Career Advice (12)
Deals (860)
Drug Development (1264)
FDA (149)
Job Trends (305)
News (8800)
Policy (343)
Tag
Academia (13)
Allergies (4)
Alliances (433)
ALS (3)
Alzheimer's disease (14)
Antibody-drug conjugate (ADC) (10)
Approvals (175)
Artificial intelligence (6)
Autoimmune disease (5)
Automation (1)
Bankruptcy (1)
Best Places to Work (309)
BIOSECURE Act (4)
Biosimilars (3)
Biotechnology (3)
Bladder cancer (14)
Brain cancer (1)
Breast cancer (15)
Cancer (162)
Cardiovascular disease (11)
Career advice (10)
CAR-T (2)
Cell therapy (12)
Cervical cancer (1)
Clinical research (1231)
Collaboration (20)
Compensation (30)
Complete response letters (2)
COVID-19 (18)
CRISPR (1)
C-suite (5)
Cystic fibrosis (2)
Data (190)
Depression (2)
Dermatology (3)
Diabetes (13)
Diagnostics (183)
Digital health (1)
Drug discovery (1)
Drug pricing (1)
Duchenne muscular dystrophy (5)
Earnings (7115)
Editorial (1)
Events (1401)
Executive appointments (23)
FDA (295)
Frontotemporal dementia (1)
Funding (23)
Gene editing (5)
Gene therapy (21)
GLP-1 (14)
Government (44)
Grass and pollen (1)
Guidances (79)
Healthcare (471)
HIV (2)
Huntington's disease (3)
IgA nephropathy (5)
Immunology and inflammation (4)
Immuno-oncology (1)
Indications (6)
Infectious disease (20)
Inflammatory bowel disease (4)
Intellectual property (6)
Interviews (4)
IPO (730)
Job creations (16)
Job search strategy (9)
Kidney cancer (1)
Layoffs (3)
Legal (60)
Liver cancer (1)
Lung cancer (35)
Lymphoma (19)
Machine learning (1)
Manufacturing (11)
MASH (8)
Medical device (339)
Medtech (342)
Mergers & acquisitions (161)
Metabolic disorders (25)
mRNA (1)
Multiple sclerosis (3)
Neurodegenerative disease (4)
Neuroscience (36)
NextGen: Class of 2026 (88)
Non-profit (16)
Obesity (4)
Ovarian cancer (2)
Pain (1)
Pancreatic cancer (2)
Parkinson's disease (7)
Partnered (1)
Patents (12)
Patient recruitment (8)
Peanut (2)
People (617)
Phase 1 (395)
Phase 2 (547)
Phase 3 (416)
Pipeline (458)
Policy (4)
Postmarket research (35)
Preclinical (146)
Prostate cancer (7)
Radiopharmaceuticals (4)
Rare diseases (13)
Real estate (23)
Regulatory (331)
Reports (1)
Research institute (17)
Resumes & cover letters (2)
Rett syndrome (2)
RSV (1)
Series A (4)
Series B (4)
Service/supplier (1)
Sickle cell disease (3)
Spinal muscular atrophy (2)
Startups (35)
Supply chain (2)
Vaccines (13)
Weight loss (2)
Women's health (4)
Date
Last 7 days (11)
Last 30 days (70)
Last 365 days (1480)
2026 (204)
2025 (1497)
2024 (971)
2023 (1228)
2022 (1329)
2021 (1432)
2020 (1203)
2019 (893)
2018 (755)
2017 (582)
2016 (381)
2015 (538)
2014 (345)
2013 (177)
2012 (232)
2011 (281)
2010 (280)
Location
Africa (6)
Alabama (2)
Arizona (4)
Asia (805)
Australia (55)
California (477)
Canada (152)
China (39)
Colorado (21)
Connecticut (18)
Delaware (11)
Europe (1733)
Florida (73)
Georgia (20)
Idaho (2)
Illinois (22)
Indiana (16)
Iowa (1)
Japan (15)
Kansas (4)
Kentucky (1)
Louisiana (4)
Maine (4)
Maryland (47)
Massachusetts (362)
Michigan (10)
Minnesota (30)
Missouri (3)
Nebraska (4)
Nevada (3)
New Hampshire (8)
New Jersey (132)
New York (141)
North Carolina (41)
Northern California (249)
Ohio (13)
Pennsylvania (116)
South America (21)
South Carolina (4)
Southern California (185)
Tennessee (6)
Texas (76)
United States (1695)
Utah (21)
Virginia (1)
Washington D.C. (2)
Washington State (28)
Wisconsin (3)
13,627 Results for "306".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Glaucoma Research Foundation Announces Record $3.06 million in Annual Research Grants to Fund their 2026 Shaffer Grants and Catalyst for a Cure Research Collaborations
March 9, 2026
·
2 min read
Deals
Corvus Pharmaceuticals Announces Pricing of $30.6 Million Registered Direct Offering
Corvus Pharmaceuticals, Inc. today announced that it has entered into a securities purchase agreement with new and existing investors to raise approximately $30.6 million dollars in aggregate gross proceeds through the sale of shares of its common stock, par value $0.0001 per share.
May 2, 2024
·
5 min read
Immunology and inflammation
Hansa Kidney Transplant Drug Aces Phase III Study, Headed to FDA
Imlifidase, an IgG-destroying enzyme, could receive FDA approval in the second half of 2026 and hit peak sales of $306 million, according to William Blair.
September 26, 2025
·
2 min read
·
Tristan Manalac
Press Releases
Atherosclerotic Cardiovascular Disease Market Size to Reach USD 30.6 Billion by 2035, Impelled by Advancements in Novel Drug Therapies
Atherosclerotic Cardiovascular Disease Market Outlook 2025-2035:
February 17, 2025
·
11 min read
Drug Development
HUTCHMED Initiates the RAPHAEL Registrational Phase III Trial of HMPL-306 for Patients with IDH1- and/or IDH2-Mutated Relapsed/Refractory Acute Myeloid Leukemia in China
HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that it has initiated a registrational Phase III clinical trial of HMPL-306 in patients with mutated isocitrate dehydrogenase (“IDH”) 1 or 2 relapsed / refractory acute myeloid leukemia (“AML”) in China. The first patient received their first dose on May 11, 2024.
May 13, 2024
·
6 min read
Press Releases
DBV Technologies Announces Financing of up to $306.9 Million (€284.5 Million) to Advance Viaskin® Peanut Patch Through Biologics License Application Submission and U.S. Commercial Launch, if Approved
March 28, 2025
·
32 min read
Drug Development
Alebund Reports Update for AP306 (EOS789), a First-in-Class Pan-inhibitor of Sodium-dependent Phosphate Transporters, from a Completed Phase II Clinical Trial in Patients with Hyperphosphatemia on Hemodialysis
Alebund Pharmaceuticals (“Alebund” or the “Company”) announced phase II proof-of-concept study results for the investigational drug, AP306, a first-in-class, pan-inhibitor of sodium-dependent phosphate transporters, which was discovered by Chugai Pharmaceutical Co., Ltd., and previously referred by EOS789.
December 13, 2023
·
4 min read
Press Releases
Pyrogen Testing Market Size to Reach USD 3.06 Billion in 2033 | Says Towards Healthcare Experts
August 13, 2024
·
13 min read
Drug Development
Instil Bio Announces Resumption of Clinical Trial of CoStAR-TIL Candidate ITIL-306 in Lung, Ovarian, and Renal Cancer
Instil Bio, Inc. (“Instil” or the “Company”) (NASDAQ: TIL) today announced the resumption of its Phase 1 clinical trial of ITIL-306 for the treatment of non-small cell lung cancer (NSCLC), ovarian cancer, and renal cell carcinoma (RCC).
January 9, 2023
·
4 min read
Drug Development
Instil Bio Announces First Patient Dosed with ITIL-306, our First Engineered TIL Therapy Using the CoStAR Platform Targeting Folate Receptor Alpha (FRα), in Non-Small Cell Lung Cancer
Instil Bio, Inc. today announced that the first patient has been dosed in a Phase 1 dose escalation study of ITIL-306 (NCT05397093) for the treatment of multiple solid tumors.
October 18, 2022
·
5 min read
1 of 1,363
Next